They Just Don't Get...
Health Care: Drugs
Depomed Inc. (DEPO: NASDAQ)
$5.01 0.01 | 0.20%
06/04/12 - 12:14 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 5.00 |
| 52 Week High | 9.26 |
| 52 Week Low | 4.20 |
| Avg. Daily Vol. (Mil) | 0.39 |
| Beta (3 year) | 1.49 |
| Share Related Items | |
| Mkt Cap (Mil) | 278.64 |
| Shares Out (Mil) | 55.73 |
| Float (Mil) | 55.27 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.90 |
| Current Ratio | 3.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 4.18 |
| Price/Book | 2.81 |
| Price/Cash Flow | -7.70 |
| Per Share Data | |
| Earnings | -0.67 |
| Sales | 1.20 |
| Book Value | 1.78 |
| Cash Flow | -0.65 |
| Business Summary | |
|---|---|
| DepoMed, Inc company, is focused on the development and commercialization of differentiated products that address large and growing markets and are based on proprietary oral drug delivery technologies. | |
| General Information | |
| 1360 O'Brien Drive
Menlo Park, CA 94025 |
|
| www.depomedinc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 110 | |
| CEO: James A. Schoeneck | |
| Short Interest | |
| Current Month (Mil) | 3.69 |
| Previous Month (Mil) | 3.84 |
| Short Interest Ratio (Days) | 8.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -24.30 |
| Return on Investments | -37.00 |
| Profitability | |
| Gross Margin | 94.10 |
| EBIT Margin | -54.60 |
| Profit Margin | -55.30 |
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
- Usergbwineman Portfolio 1
- UserLTR7181 Portfolio 1
- Userfrankie'spicks
Latest DEPO Headlines from TheStreet
- Stocks Under $10: Healthcare Name on Sale
05.17.12 | 07:05 am - Depomed: After-Hours Trading 02.03.12 | 05:02 pm
- Depomed Stock Hits New 52-Week Low (DEPO) 10.18.11 | 10:10 am
- Depomed Stock Gaps Down On Today's Open (DEPO) 10.14.11 | 09:10 am
- 7 Stocks to Watch: Google, Apple 10.14.11 | 07:10 am
- Google, Depomed: After-Hours Trading 10.13.11 | 05:10 pm
- Acadia Pharmaceuticals: Investing With No Safety Net 06.24.11 | 10:06 am
- Biotech Stock Mailbag: Star Scientific 03.18.11 | 07:03 am
- 5 Stocks to Watch: Sanmina, UBS 03.17.11 | 07:03 am
- Guess?, DepoMed: After-Hours Trading 03.16.11 | 05:03 pm
Press Releases for DEPO
- Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf - PR Newswire 05.29.12 | 08:05 am
- Depomed To Present At Jefferies 2012 Global Health Care Conference - PR Newswire 05.25.12 | 08:05 am
- Depomed To Present At Bank Of America Merrill Lynch 2012 Health Care Conference - PR Newswire 05.10.12 | 08:05 am
- New 60,000 Square Foot Lease At The Pacific Research Center Signed By Biomed Realty And Depomed - PR Newswire 04.09.12 | 04:04 pm
- Santarus And Depomed Announce Settlement With Lupin Of GLUMETZA Patent Litigation - Business Wire 02.22.12 | 04:02 pm
- Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products - Business Wire 08.22.11 | 05:08 am
- Ironwood Pharmaceuticals And Depomed Announce Collaboration, Research And License Agreement - Business Wire 07.27.11 | 04:07 pm
- Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets - Business Wire 01.05.11 | 04:01 am
- New Clinical Study Shows Patients With Type 2 Diabetes May Be Able To Tolerate Higher Doses Of Metformin Using GLUMETZA - PR Newswire 06.28.10 | 08:06 am
- Depomed To Present At The 9th Annual JMP Securities Research Conference - Business Wire 05.04.10 | 08:05 am
Partner Headlines for DEPO
- New Constructs' Most Attractive Stocks for June - Benzinga 06.04.12 | 09:06 am
- The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - Zacks 05.18.12 | 09:05 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows - Seeking Alpha 02.03.12 | 07:02 pm
- Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck - Benzinga 02.03.12 | 04:02 pm
- Depomed Receives Notice of Paragraph IV Certification Against Patents for Gralise - Benzinga 01.23.12 | 04:01 pm
- BMS Drug Deemed Too Costly: Weekly Round-Up Of Biotech Failures And Mishaps - Seeking Alpha 10.16.11 | 08:10 am
- UPDATE: Zacks Upgrades DepoMed from Neutral to Outperform - Benzinga 08.10.11 | 09:08 am
- 5 Highly Profitable Stocks Undervalued by EPS Trends - Seeking Alpha 07.11.11 | 06:07 am
- Contrarian Ideas: 25 High Growth Stocks With Significant Short Selling - Seeking Alpha 06.06.11 | 08:06 am
